[The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].

Y T Liu、Y S Gao、Y S Mao、Jing Jiang、Lei Yang、J. Yang、Xingsheng Hu、Shengyu Zhou

2020PubMedMedicine被引 4

摘要

Immunotherapy combined with chemotherapy as a neoadjuvant treatment is an effective, low-toxicity treatment manner, which has perioperative safety and high rate of MPR for patients with resectable NSCLC. It is a promising treatment option for patients with stage Ⅱ to Ⅲ NSCLC.

引用本文（GB/T 7714）

Y T Liu, Y S Gao, Y S Mao, 等. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].[J]. PubMed, 2020.

引文网络

参考文献与被引分析加载中…

DOI：https://doi.org/10.3760/cma.j.cn112152-20200213-00087

本站仅收录题录与摘要供学习参考，全文版权归属出版方；如有侵权请联系我们删除。